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Abstract
The new adult heart allocation policy was approved in 2016 and im-
plemented in October 2018, so its effect was not yet evident in 2018 data.
However, the more granular data being collected are anticipated to al-
low for improved analyses. In 2018, new listings continued to increase;
3883 new adult and 685 new pediatric candidates were added. In 2018,
3440 heart transplantswere performed, an increase of 167 over 2017; 473
transplants occurred in pediatric recipients and 2967 in adult recipients.
Short-term and long-term posttransplant mortality improved. Overall 1-
year survival for adults who underwent heart transplant in 2011-2013was
90.3%, 3-year survival was 84.7%, and 5-year survival was 79.6%. Mortality
rates for pediatric recipients were 4.5% at 6 months and in 5.9% at 1 year
posttransplant, 12.5% at 3 years for transplants in 2014-2015, 14.8% at 5
years for transplants in 2012-2013, and 29.8% at 10 years for transplants
performed in 2008-2009.






The new adult heart allocation policy was approved in 2016 and implemented
in October 2018. Its goal is to better stratify heart transplant candidates and to
broaden sharing for higher urgency statuses to reducewaitlistmortality. While
it is too early to discern the impact of the new policy, the more granular data
being collected as part of the new systemare anticipated to allow for improved
analyses of outcomes and risk factors, whichwill contribute to amore dynamic
policy. The current Annual Data Report provides an early glimpse into the
distribution of patients under the new allocation system.
2 Adult Heart Transplant
2.1 Waitlist Trends
Between 2009 and 2018, the number of new active listings for heart transplant
increased by 33.7%, from 2810 to 3756 (Figure HR 1). The number of candi-
dates actively awaiting heart transplant increased by 39.7% since 2009, from
1858 to 2596 (Figure HR 2); however, since 2015, the number of active patients
on the list at the end of the year declined, and the number of inactive pa-
tient declined then increased slightly. Some remarkable demographic trends
in heart transplantation include the following: a continued increase in the pro-
portion of heart transplant candidates aged 65 years or older to 18.7% in 2018
(Figure HR 3); stable proportions of racial/ethnic minorities, with black candi-
dates comprising a slightly smaller proportion of waitlist candidates, 24.8%,
and whites candidates a slightly higher proportion, 62.4% (Figure HR 5); and a
slight increase in patients with congenital heart disease (Figure HR 6). In 2018,
63% of candidates had been on the waiting list for less than 1 year, a slight
increase since 2008. In 2008, 12.9% of candidates had been on the waiting
list 5 years or longer; this proportion gradually declined to 4.0% in 2018, the
lowest in the past decade (Figure HR 7). The proportion of candidates await-
ing transplant as status 1A continued to increase, 48.1% in 2018 (Figure HR
8). The proportion of status 1B candidates increased similarly but reached a
plateau over the past 4 years, while the proportion waiting as status 2 declined
from 25.7% in 2008 to 14.2% in 2018. Note that new status groups in use as
of October, 2018 were converted to former status 1A, 1B and 2 equivalents
for the 2018 data point (see Preface). The proportion of candidates with ven-
tricular assist devices (VADs) at listing increased from 11.8% in 2008 to 32.6%
in 2018 (Figure HR 9). Sex distribution has not changed appreciably: in 2018,
women comprised 26% of heart transplant candidates (Figure HR 4). In 2018,
85.5% of candidates resided in a metropolitan area (Table HR 1).The propor-
tion of candidates within 50 miles of the transplant program increased from
56.3% in 2008 to 62.1% in 2018, and proportions of those at greater distances
decreased. Candidates with a prior heart transplant declined from 4.3% in




 heart-kidney transplant, a substantial increase since 2008, while those listed
for heart-lung transplants decreased to only 42 (1.23%) in 2018 (Table HR 3).
The distribution of candidates by status on December 31 in 2017 and 2018
is shown in Table HR 4. At the end of 2018, 47.8% of candidates were listed
as new status 4, similar to the proportion listed as former status 1B at the
end of 2017. Only 7 patients, or 0.2%, were listed as new status 1 (Table HR 4).
The number of patients receiving any life support prior to transplant increased
from 1791 in 2013 to 2402 in 2018 (Table HR 7). Of these, 43.6% had left VADs
(LVADs), an increase of 342 over the 5-year period. While the proportion of
LVADs and inotropes declined slightly since 2013, intra-aortic balloon pump
(IABP) use increased from 5.7% to 9.1% and extracorporeal membrane oxy-
genation (ECMO) use increased from 0.7% to 2.0%. In 2018, 270 candidates
used IABP, compared with 123 in 2013, and 58 used ECMO, compared with 15
in 2013. Candidates with total artificial hearts and right VADs declined to just
1% and 1.6%, respectively (Table HR 7).
Between 2008 and 2018, heart transplant rates fluctuated, reaching a nadir
of 61.5 per 100 waitlist-years in 2015, followed by an increase to a decade high
of 82.0 per 100 waitlist-years in 2018 (Figure HR 14). This trend was similar for
all age groups, blood types, and status groups (Figure HR 11, Figure HR 13,
Figure HR 14). For most groups, transplant rates since 2007 reached a nadir
in 2014 and 2015 and have increased since. Trends were similar for black and
Hispanic candidates, but transplant rates did not recover at the same magni-
tude as for other groups and overall declined since 2008. The transplant rate
for blacks declined from82.0 per 100waitlist-years in 2008 to 69.2 in 2018, and
for Hispanics from 90.2 per 100 waitlist-years to 80.Transplant rates increased
in all age groups since 2015, but to a greater extent for candidates aged 65 or
older. The transplant rate for these candidates exceeded that for all the other
age groups, at 109.4 per 100 waitlist-years. Despite the overall increase, the
transplant rate remained lowest for candidates aged 35-49 years, 69.6 per 100
waitlist-years.
Transplant rates have consistently been highest for candidates with blood
type AB (199.4 per 100 waitlist-years) and for those listed as status 1A (302.2
per 100 waitlist-years). In 2018, blood type O candidates underwent trans-
plant at a rate of 58.0 per 100 waitlist-years, nearly half the rate of blood type
A and B candidates and 29% of the rate of blood type AB candidates. Can-
didates with blood type A underwent transplant at a rate of 106.1 per 100
waitlist-years, higher than in previous years, and higher than candidates with
blood type B. Despite a decline in transplant rates between 2007 and 2015,
since then, rates have increased for nearly all groups. In 2018, candidates re-
siding in non-metropolitan areas underwent transplant at slightly higher rates
than those in metropolitan areas, 84.6 per 100 waitlist-years vs. 81.7 (Figure
HR 15). Although trends based on candidate distance from the donor hospital
have been similar over the past decade, in 2018, candidates residing 100-<250
nautical miles (NM) from the donor hospital underwent transplant at the high-




 the lowest rate, 80.4 per 100 waitlist-years (Figure HR 16).
The median waiting time in 2017-2018 was 6.9 months (Figure HR 18). The
lowest median time to transplant of the decade occurred in 2007-2008. A
peak of 11.6 months occurred in 2013-2014, followed by a gradual decline.
In 2017-2018, median waiting time was longest for blood type O candidates,
13.5 months (Figure HR 19); status 2 candidates, 16.72 months; and candi-
dates with body mass index ? 31 kg/m2, 11.2 months (Figure HR 20, Figure HR
21). Waiting time decreased for all status groups and was lowest for status
1A, 1.97 months. Women waited on average 4.9 months, andmen 7.9 months
(Figure HR 18). Median waiting time was lowest of all groups for candidates
with blood type AB, 1.5 months. Since 2007, the proportion of candidates un-
dergoing transplantwithin 1 year of listing declined overall, but increased from
48.6% in 2014 to 57.2% in 2017. Of candidates listed in 2017, 33.3% underwent
transplant within 3 months and 45.5% within 6 months (Figure HR 22). When
stratified by donation service area (DSA), the proportion of candidates under-
going transplant within 1 year of listing in 2017 varied from 23.1% to 94.1%
(Figure HR 23). Similar variability occurred by state, ranging from 25.0% to
100% (n = 3) (Figure HR 24).
Among candidates listed in 2015, 51.5% underwent transplant during the
first year on the waiting list, 31.9% were still waiting, 9.4% were removed from
the list, and 7.2% had died (Figure HR 17). At 3 years, 66.0% had undergone
transplant, 8.1% were still waiting, 17.4% had been removed from the list, and
8.5% had died.
Since 2007-2008, pretransplantmortality declined from 16.6 to 10.8 deaths
per 100 waitlist-years in 2017-2018 (Figure HR 25). Pretransplant mortality de-
clined for all groups except candidates with valvular heart disease, unknown
etiology, and unknown ethnicity. Pretransplantmortality was lowest for candi-
dates aged 18-34 years and those listed as status 2, 7.3 deaths per 100waitlist-
years. Pretransplantmortality declined bymore than 50% for candidates aged
18-34 years, from 15.4 per 100 wait-list deaths in 2007-2008 to 7.3 in 2017-
2018 (Figure HR 25, Figure HR 29). Pretransplant mortality declined substan-
tially over the past decade for black, Hispanic, and Asian candidates. In 2017-
2018, pretransplantmortalitywas lowest for blacks, 9.2 deaths per 100waitlist-
years (Figure HR 26). In 2007-2008, pretransplant mortality for LVAD candi-
dates was more than twice that for non-LVAD candidates, 38.3 vs. 15.0 deaths
per 100 waitlist-years. However, pretransplant mortality declined substan-
tially for LVAD candidates, to 10.2 deaths per 100 waitlist-years in 2017-2018.
Pretransplantmortality for non-VAD candidateswas 11.1 deaths per 100waitlist-
years in 2017-2018. Since 2013-2014, pretransplant mortality has been lower
in VAD than in non-VAD candidates (Figure HR 30). Pretransplant mortality
rates remained highest among candidates listed as status 1A, as might be ex-
pected, but declined dramatically between 2007-2008 and 2009-2010, from
71.9 deaths per 100 waitlist-years to 49.3 (Figure HR 29), followed by a gradual
decline to 30.1 in 2017-2018. Similarly, pretransplant mortality among can-




 years. Pretransplant mortality was slightly higher for candidates residing in
nonmetropolitan areas than for those in metropolitan areas (Figure HR 31),
and varied by DSA from 3.3 to 25.1 deaths per 100 waitlist-years (Figure HR
34).
Among candidates removed from the waiting list for reasons other than
transplant, 16.9%diedwithin 6months of removal in 2018, although data from
only the first half of 2018 were available. The overall trend showed a decline
in patients who died within 6 months of removal from the waiting list, despite
fluctuation and an increase to 33.2% in 2013 (Figure HR 35). In 2017, 172 pa-
tients died within 6 months of removal from the waiting list. In 2017, 47.9%
of candidates listed as status 1A died within 6 months of removal. The per-
centage of candidates aged 18-34 years who died within 6 months followed a
similar trend and decreased to 7.7% in 2017, but increased to 19.5% in 2018
(Figure HR 36).
2.2 Donor Trends
The number of deceased heart donations continued to increase; 3443 de-
ceased donors in 2018was the highest number to date, and an increase of 52%
since 2007. While the number of donors increased in all age groups over the
past decade, the greatest increase was donors aged 18-34 years, from 1039 in
2008 to 1706 in 2018 (Figure HR 37); the highest proportion of donors, 50%,
were in this age group (Figure HR 38). Among donors 2014-2018, the number
of pediatric heart donors in a DSA ranged from 2 to 164. The proportion of pe-
diatric donor hearts that were transplanted into adults varied by DSA from 0%
to 64% (Figure HR 41). The rate of discards, that is, the proportion of recovered
hearts that were not transplanted, has fluctuated over the past decade and in
2018 was 0.8% (Figure HR 42). Although discards were highest in age group 50
years or older, they declined in this age group from 3.3% in 2015-2016 to 1.8%
in 2017-2018. The discard rate for Public Health Service (PHS) high risk donors
was 1.0% compared with 0.7% for non-PHS high risk donors (Figure HR 43).
Head trauma as cause of donor death continued to decline in prevalence
and in 2018 was 43.0%. Conversely, anoxia continued to increase in preva-
lence to 41.6% of donors in 2018, second to head trauma (Figure HR 44). In
2007, anoxia was the cause of death for only 15.0% of donors. The increase in
anoxic deaths may be partially attributable to the rise in opioid deaths.
2.3 Overall Trends in Heart Transplant
The general trend has been an increase in heart transplants over the past
decade (Figure HR 45). In 2018, 3440 heart transplants were performed, an in-
crease of 167 over 2017; 473 transplants occurred in pediatric recipients and
2967 in adult recipients (Figure HR 45). Pediatric heart transplants declined
between 2015 and 2017, but increased by 41 since then. In 2018, six fewer




 increased for all other age groups, with the largest number, 1407, in recipi-
ents aged 50-64 years (Figure HR 46). In 2018, 2028 heart transplants were
performed for cardiomyopathy (Figure HR 49). The number of recipients who
underwent transplant at status 1A more than doubled, from 1108 in 2007 to
2439 in 2018, representing 71% of all transplants. The number of status 1B
recipients has fluctuated, but decreased from 954 in 2017 to 868 in 2018. Of
note, 133 transplants were performed in status 2 patients, the highest since
2011 and an increase of 48 over 2017 (Figure HR 50). Note that new status
groups in use as of October, 2018 were converted to former status 1A, 1B and
2 equivalents for the 2018 data point.
In 2018, 84.2% of recipients resided in metropolitan areas, and 61.2% lived
within 50miles of the transplant program (Table HR 8). In 2018, 46.2% of recip-
ients had LVADs. The number of recipients with VADs at the time of transplant
increased from 519 in 2013 to 1370 in 2018 (Table HR 9). Although 28.9% of
patients underwent transplant within 31 days of listing in 2018, the proportion
who waited 1 year or longer increased over the past decade: 18.3% in 2018 vs.
9.5% in 2008 (Table HR 10). Multi-organ transplant accounted for 9.1% of heart
transplants; 202 heart-kidney transplants were performed in 2018 compared
with 63 in 2008 (Table HR 10).
Use of induction therapy has changed little since 2007. In 2018, 51.7% of
adult heart transplant recipients received either IL2-RA or T-cell depleting ther-
apy (Figure HR 51), 96.6% received a tacrolimus-based immunosuppression
regimen, and 3.4% received other regimens (Figure HR 52).
In 2018, the median transplant program volume was 19 transplants per
year, increased since 2008, but at a plateau since 2015 (Figure HR 54). The
percentage transplants performed at low-volume programs (0 to 9 transplants
per year) declined to 4.0% in 2018, compared with 10.7% in 2008. The propor-
tion transplants performed at programs with volumes of 60 or more trans-
plants fluctuated, peaking at 21.1% in 2017 and declining to 15.5% in 2018
(Figure HR 55). Overall, however, high-volume programs have increased over
the past decade. Between 2007 and 2015, most heart transplants occurred at
programs performing 10-29 per year; more recently, this shifted to programs
performing 30-59 transplants per year, where 44.6% were performed in 2018
(Table HR 55).
2.4 Posttransplant Survival and Morbidity
Overall 1-year survival for patients who underwent heart transplant in 2011-
2013 was 90.3%, 3-year survival was 84.7%, and 5-year survival was 79.6% (Fig-
ure HR 56). One-year survival in most subgroups was similar, but tended to
be lower among recipients aged 65 years or older (Figure HR 56) and Hispanic
recipients (Figure HR 57). Survival tended to be better for Asian recipients at
all time-points. Survival at 1 year was similar for recipients with VADs, IABPs,
and without circulatory support; however, survival was lower at 3 and 5 years




 survival was lower for re-transplant recipients, but by 5 years was similar to
those undergoing a first transplant (Figure HR 60). Survival tended to beworse
for recipients residing 250 miles or farther from the transplant program than
for those residing closer at 1, 3, and 5 years, and was the lowest 1-, 3-, and
5-year survival of all groups (Figure HR 63). Since 2001, short- and long-term
death rates have declined. Among recipients who underwent transplant In
2017, 7.0% died at 6 months and 9.0% died at 1 year (Figure HR 64). Ten-year
mortality remained high at 38.2% among those who underwent transplant in
2008, although this has declined from 43.0% among those who underwent
transplant in 2001. The number of heart transplant survivors has increased
by over 11,000 since 2007. On June 30, 2018, 33,885 heart transplant recipi-
ents were alive with a functioning graft, compared with 32,151 in 2017. Most
survivors were aged 50 years or older at the time of transplant (Figure HR 65).
The incidence of acute rejection in the first year posttransplant was 27.0%
for recipients undergoing transplant in 2016-2017 (Figure HR 66). Rejection
occurred more frequently in younger patients, 32.0% of recipients aged 18-34
years compared with 23.1% of those aged 65 years or older. Posttransplant
lymphoproliferative disorder (PTLD) occurred in 1.0% of recipients by year 5,
but more frequently, 3.5%, in those who were seronegative for Epstein Barr
virus (EBV) (Figure HR 68). The most common documented cause of death in
the first posttransplant year was cardiovascular/cerebrovascular disease (Fig-
ure HR 69), and in years 2 through 5 (Figure HR 70). Malignancy was a relatively
infrequent cause of death, 1.4% at 5 years (Figure HR 70).
3 Pediatric Heart Transplant
3.1 Pediatric Waitlist Trends
In 2018, 685 newpediatric candidateswere added to the heart transplant wait-
ing list, with few at inactive status (Figure HR 71). At year-end 2018, 395 candi-
dates listed before their eighteenth birthdays were awaiting heart transplant,
73.2% active (Figure HR 72). Over the past decade, the proportion of inactive
candidates at year-end decreased from 56.9% in 2007 to 26.8% in 2018. The
largest pediatric age group on the waiting list in 2018 was 11-17 years (33.4%),
followed by 1-5 years (26.9%), younger than 1 year (26.1%), and 6-10 years
(13.6%) (Figure HR 73). Just over half of pediatric heart transplant candidates
were white, 20.6% were black, 19.6% were Hispanic, and 4.2% were Asian (Fig-
ure HR 74). Over the past decade, the proportion of pediatric heart candidates
with congenital defects increased from 41.6% in 2007 to 55.8% in 2018 (Figure
HR 75). Considering trends over time, the age and race of waitlisted candi-
dates has remained relatively unchanged (Table HR 13). For candidates wait-
ing on December 31, 2018, congenital defect was the leading cause of heart
disease at 62.2%, increased from48.0% in 2008 (Table HR 14). The proportions
of heart transplant candidates listed as status 1B and status 2 increased over




 implemented in 2016. The percentage of candidates using VADs at the time
of listing remained stable, from 4.0% in 2008 to 6.6% in 2018 (Table HR 14). A
smaller proportion of candidates were listed for heart-lung transplant in 2018,
0.6% compared with 5.6 % in 2008 (Table HR 15). Among the 674 candidates
removed from the waiting list in 2018, 486 (72.1%) were removed due to un-
dergoing transplant, 77 (11.4%) died, 62 (9.2%) were removed due to improved
condition, and 31 (4.6%) were considered too sick to undergo transplant (Table
HR 16, Table HR 17).
Just over 70% of pediatric candidates newly listed in 2015 underwent trans-
plant within 3 years, 13.0% died, 11.8% were removed from the list, and 4.2%
were still waiting (Figure HR 79). The rate of heart transplants among pedi-
atric waitlist candidates has remained relatively stable over the past decade,
and was 117.7 per 100 waitlist-years in 2018 (Figure HR 80). Transplant rates
varied by age; rates were highest for candidates aged younger than 1 year, at
183.0 transplants per 100 waitlist-years in 2018, followed by candidates aged
11-17 years, at 117.7 transplants per 100 waitlist-years (Figure HR 80). Pre-
transplant mortality decreased over the past decade, from 27.6 deaths per
100 waitlist-years in 2007-2008 to 17.6 in 2017-2018 (Figure HR 83). By age,
pretransplant mortality rates were highest for candidates aged younger than
1 year, at 41.1 deaths per 100 waitlist-years in 2017-2018, followed by 14.4
deaths per 100 waitlist-years for ages 1-5 years, 11.1 for ages 6-10 years, and
7.1 for ages 11-17 years (Figure HR 83). By medical urgency status, pretrans-
plant mortality was highest for status 1A (46.6 deaths per 100 waitlist-years)
and 1B (11.4) candidates, compared with 3.7 for status 2 candidates (Figure
HR 85).
3.2 Pediatric Trends in Heart Transplant
Pediatric transplant recipients are defined as those aged 18 years or younger
at the timeof transplant. Thenumber of pediatric heart transplants performed
each year continued to increase, to 473 in 2018 from 330 in 2007 (Figure HR
89). In 2018, 27 of 138 total heart transplant programs performed pediatric
heart transplants exclusively, 77 performed only adult heart transplants, and
26 performed both adult and pediatric heart transplants (Figure HR 90). In
2018, 7.8% of transplants in recipients aged younger than 10 years were per-
formed at programs with volume of five or fewer pediatric transplants in that
year (Figure HR 91). Over the past decade, the age, sex, and race/ethnicity
of pediatric heart transplant recipients changed little (Table HR 18).The pro-
portion of recipients with private insurance decreased over the decade and
the proportion with Medicaid increased (Table HR 18). Congenital defects re-
mained the most common primary cause of disease, affecting 50.1% of recip-
ients who underwent transplant in 2016-2018 (Table HR 19). The proportion
of patients who underwent transplant at status 1A and 1B increased over the
decade, and theproportion at status 2 decreased. VADuse at the timeof trans-




 2016-2018 (Table HR 19). The proportion of ABO-incompatible transplants in
2016-2018 increased 3-fold to 9.9% from 3.3% a decade earlier (Table HR 20).
In 2018, use of T-cell depleting agents for induction continued to increase,
to 74.6% of pediatric heart transplant recipients; use of interleukin-2 recep-
tor antagonists decreased to 8.2% (Figure HR 92). The initial immunosup-
pression regimen used most commonly shifted in 2018 to more recipients
using tacrolimus and MMF (47.5%) with a reciprocal decrease in those using
tacrolimus, MMF, and steroid (39.0%) (Figure HR 93).
3.3 Pediatric Posttransplant Survival and Morbidity
Among pediatric heart transplant recipients 2016-2017, the rate of acute rejec-
tion in the first year was 18.8% overall; the highest rate was 23.4% in recipients
aged 11-17 years, and the lowest was 15.8% in recipients aged younger than 6
years (Figure HR 96). Among pediatric heart transplant recipients 2016-2018,
the combination of a CMV-positive donor andCMV-negative recipient occurred
in 28.1% of transplants; for EBV, this combination occurred in 28.7% of trans-
plants (Table HR 22).
Recipient death occurred in 4.5% of patients at 6 months posttransplant
and in 5.9% at 1 year posttransplant among pediatric heart transplants per-
formed in 2016-2017, in 12.5% of patients at 3 years posttransplant for trans-
plants performed in 2014-2015, in 14.8% of patients at 5 years posttransplant
for transplants performed in 2012-2013, and in 29.8% of patients at 10 years
posttransplant for transplants performed in 2008-2009 (FigureHR99). Overall,
1-year and 5-year patient survival were 90.9% and 81.5%, respectively, among
recipients who underwent transplant in 2006-2013 (Figure HR 100). By age, 5-
year patient survival was 76.9% for recipients aged younger than 1 year, 82.9%
for ages 1-5 years, 87.1% for ages 6-10 years, and 82.4% for ages 11-17 years
(Figure HR 100). The leading identified causes of death in the first 12 months
posttransplant among recipients from 2016-2017 were infection (1.4%) and
cardio/cerebrovascular disease (1.4%) (Figure HR 101). At 5 years posttrans-
plant, the leading causes were graft failure (3.9%) and cardio/cerebrovascular
disease (3.7%) (Figure HR 102).
The overall incidence of PTLDwas 4.1% at 5 years posttransplant; incidence
was 5.3% among EBV-negative recipients and 3.1% among EBV-positive recip-
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Figure HR 1. New adult candidates added to the heart transplant wait-
ing list. A new candidate is one who first joined the list during the given year,
without having been listed in a previous year. Previously listed candidateswho
underwent transplant and subsequently relisted are considered new. Candi-
dates concurrently listed at multiple centers are counted once. Active and in-
active patients are included.















Figure HR 2. Adults listed for heart transplant on December 31 each year.
Candidates concurrently listed at multiple centers are counted once. Those


















Figure HR 3. Distribution of adults waiting for heart transplant by age.
Candidates waiting for transplant at any time in the given year. Candidates
listed concurrently at multiple centers are counted once. Age is determined
at the later of listing date or January 1 of the given year. Active and inactive
candidates are included.













Figure HR 4. Distribution of adults waiting for heart transplant by sex.
Candidates waiting for transplant at any time in the given year. Candidates





















Figure HR 5. Distribution of adults waiting for heart transplant by race.
Candidates waiting for transplant at any time in the given year. Candidates
listed concurrently at multiple centers are counted once. Active and inactive
candidates are included.














Figure HR 6. Distribution of adults waiting for heart transplant by diag-
nosis. Candidates waiting for transplant at any time in the given year. Can-
didates listed concurrently at multiple centers are counted once. Active and





















FigureHR7. Distributionof adultswaiting for heart transplant bywaiting
time. Candidates waiting for transplant at any time in the given year. Candi-
dates listed concurrently at multiple centers are counted once. Time on the
waiting list is determined at the earlier of December 31 or removal from the
waiting list. Active and inactive candidates are included.















Figure HR 8. Distribution of adults waiting for heart transplant by medi-
cal urgency. Candidates waiting for transplant at any time in the given year.
Candidates listed concurrently at multiple centers are counted once. Medical
urgency status is the most severe during the year. New status codes in use
as of October 18, 2018 were converted to their old status equivalents for the




















Figure HR 9. Distribution of adults waiting for heart transplant by VAD
status at listing. Candidates waiting for transplant at any time in the given
year. Candidates listed concurrently at multiple centers are counted once.
Active and inactive patients are included. VAD, ventricular assist device.













Figure HR 10. Distribution of adults waiting for heart transplant by blood
type. Candidates waiting for transplant at any time in the given year. Can-
didates listed concurrently at multiple centers are counted once. Active and

































Figure HR 11. Deceased donor heart transplant rates among adult wait-
list candidates by age. Transplant rates are computed as the number of de-
ceased donor transplants per 100 patient-years of wait time in a given year.
Individual listings are counted separately. Age is determined at the later of list-
ing date or January 1 of the given year. Rates with less than 10 patient-years
of exposure or fewer than 20 candidates at risk are not shown.





























Figure HR 12. Deceased donor heart transplant rates among adult wait-
list candidates by race. Transplant rates are computed as the number of de-
ceased donor transplants per 100 patient-years of wait time in a given year. In-
dividual listings are counted separately. Rates with less than 10 patient-years


































Figure HR 13. Deceased donor heart transplant rates among adult wait-
list candidates by blood type. Transplant rates are computed as the num-
ber of deceased donor transplants per 100 patient-years of wait time in a
given year. Individual listings are counted separately. Rates with less than 10
patient-years of exposure or fewer than 20 candidates at risk are not shown.






























Figure HR 14. Deceased donor heart transplant rates among adult wait-
list candidates by medical urgency. Transplant rates are computed as the
number of deceased donor transplants per 100 patient-years of wait time in
a given year. Individual listings are counted separately. Medical urgency is as-
sessed at the time of listing. New status codes in use as of October 18, 2018
were converted to their old status equivalents for the 2018 data point. Rates


































Figure HR 15. Deceased donor heart transplant rates among adult wait-
list candidates by metropolitan vs. non-metropolitan residence. Trans-
plant rates are computed as the number of deceased donor transplants per
100 patient-years of wait time in a given year. Individual listings are counted
separately. Urban/rural determination is made using the RUCA (Rural-Urban
Commuting Area) designation of the candidate’s permanent zip code. Rates
with less than 10 patient-years of exposure or fewer than 20 candidates at risk
are not shown.






























Figure HR 16. Deceased donor heart transplant rates among adult wait-
list candidates by distance from listing center. Transplant rates are com-
puted as the number of deceased donor transplants per 100 patient-years of
wait time in a given year. Individual listings are counted separately. Distance
is nautical miles (NM) between the zip code centroids of the candidate’s listing
center and candidate’s permanent zip code. Rates with less than 10 patient-





















Figure HR 17. Three-year outcomes for adults waiting for heart trans-
plant, new listings in 2015. Adults waiting for heart transplant and first listed
in 2015. Candidates concurrently listed at more than one center are counted



















Figure HR 18. Medianmonths to heart transplant for waitlisted adults by
sex. Observations censored on December 31, 2018; Kaplan-Meier competing
riskmethods used to estimate time to transplant. Analysis performed per can-
didate, not per listing. If an estimate is not plotted, 50% of the cohort listed in





















Figure HR 19. Median months to heart transplant for waitlisted adults
by blood type. Observations censored on December 31, 2018; Kaplan-Meier
competing risk methods used to estimate time to transplant. Analysis per-
formed per candidate, not per listing. If an estimate is not plotted, 50% of the
cohort listed in that year had not undergone transplant by the censoring date.
















Figure HR 20. Medianmonths to heart transplant for waitlisted adults by
medical urgency at listing. Observations censored on December 31, 2018;
Kaplan-Meier competing risk methods used to estimate time to transplant.
Analysis performed per candidate, not per listing. If an estimate is not plot-
ted, 50% of the cohort listed in that year had not undergone transplant by the
censoring date. Only the first transplant is counted. New status codes in use




















Figure HR 21. Median months to heart transplant for waitlisted adults
by BMI at listing. Observations censored on December 31, 2018; Kaplan-
Meier competing risk methods used to estimate time to transplant. Analysis
performed per candidate, not per listing. If an estimate is not plotted, 50% of
the cohort listed in that year had not undergone transplant by the censoring
date. Only the first transplant is counted.















FigureHR 22. Percentage of adultswhounderwent deceased donor heart
transplant within a given time period of listing. Candidates concurrently
listed at more than one center are counted once, from the time of earliest
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FigureHR 23. Percentage of adultswhounderwent deceased donor heart
transplant within 1 year of listing in 2017 by DSA. Candidates listed concur-
rently in a single DSA are counted once in that DSA, from the time of earliest
listing to the time of latest removal; candidates listed in multiple DSAs are
counted separately per DSA.
No data
25.0 100.0
44.4 52.4 59.0 67.8
FigureHR 24. Percentage of adultswhounderwent deceased donor heart
transplantwithin 1 year of listing in 2017by state. Candidates concurrently
listed at more than one center are counted once, from the time of earliest


































Figure HR 25. Pretransplant mortality rates among adults waitlisted for
heart transplant by age. Mortality rates are computed as the number of
deaths per 100 patient-years of waiting in the given year. Waiting time is cen-
sored at transplant, death, transfer to another program, removal because of
improved condition, or end of cohort. Individual listings are counted sepa-
rately. Rates with less than 10 patient-years of exposure or fewer than 20
candidates at risk are not shown. Age is determined at the later of listing date































Figure HR 26. Pretransplant mortality rates among adults waitlisted for
heart transplant by race. Mortality rates are computed as the number of
deaths per 100 patient-years of waiting in the given year. Waiting time is cen-
sored at transplant, death, transfer to another program, removal because of
improved condition, or end of cohort. Individual listings are counted sepa-
rately. Rates with less than 10 patient-years of exposure or fewer than 20































Figure HR 27. Pretransplant mortality rates among adults waitlisted for
heart transplant by sex. Mortality rates are computed as the number of
deaths per 100 patient-years of waiting in the given year. Waiting time is cen-
sored at transplant, death, transfer to another program, removal because of
improved condition, or end of cohort. Individual listings are counted sepa-
rately. Rates with less than 10 patient-years of exposure or fewer than 20




























Figure HR 28. Pretransplant mortality rates among adults waitlisted for
heart transplant by diagnosis. Mortality rates are computed as the number
of deaths per 100 patient-years of waiting in the given year. Waiting time is
censored at transplant, death, transfer to another program, removal because
of improved condition, or end of cohort. Individual listings are counted sep-
arately. Rates with less than 10 patient-years of exposure or fewer than 20

































Figure HR 29. Pretransplant mortality rates among adults waitlisted for
heart transplant by medical urgency. Mortality rates are computed as the
number of deaths per 100 patient-years of waiting in the given year. Wait-
ing time is censored at transplant, death, transfer to another program, re-
moval because of improved condition, or end of cohort. Individual listings are
counted separately. Rateswith less than 10 patient-years of exposure or fewer
than 20 candidates at risk are not shown. Medical urgency is determined at

























Figure HR 30. Pretransplant mortality rates among adults waitlisted for
heart transplant byVADat listing. Mortality rates are computed as the num-
ber of deaths per 100 patient-years of waiting in the given year. Waiting time is
censored at transplant, death, transfer to another program, removal because
of improved condition, or end of cohort. Individual listings are counted sep-
arately. Rates with less than 10 patient-years of exposure or fewer than 20































Figure HR 31. Pretransplant mortality rates among adults waitlisted for
heart by metropolitan vs. non-metropolitan residence. Mortality rates
are computed as the number of deaths per 100 patient-years of waiting in the
given year. Waiting time is censored at transplant, death, transfer to another
program, removal because of improved condition, or end of cohort. Individual
listings are counted separately. Rates with less than 10 patient-years of expo-
sure or fewer than 20 candidates at risk are not shown. Urban/rural determi-
nation is made using the RUCA (Rural-Urban Commuting Area) designation of

































Figure HR 32. Pretransplant mortality rates among adults waitlisted for
heart, by distance from listing center. Mortality rates are computed as the
number of deaths per 100 patient-years of waiting in the given year. Wait-
ing time is censored at transplant, death, transfer to another program, re-
moval because of improved condition, or end of cohort. Individual listings are
counted separately. Rateswith less than 10 patient-years of exposure or fewer
than 20 candidates at risk are not shown. Distance is nautical miles (NM) be-































Figure HR 33. Pretransplant mortality rates among adults waitlisted for
heart, by active/inactive status. Mortality rates are computed as the num-
ber of deaths per 100 patient-years of waiting in the given year. Waiting time is
censored at transplant, death, transfer to another program, removal because
of improved condition, or end of cohort. Individual listings are counted sep-
arately. Rates with less than 10 patient-years of exposure or fewer than 20
candidates at risk are not shown. Status (active/inactive) is assessed on the
later of January 1 of the given year and listing date.
No data
3.3 25.4
8.3 10.0 12.2 14.0
Figure HR 34. Pretransplant mortality rates among adults waitlisted for
heart transplant in 2017-2018, by DSA.Mortality rates are computed as the
number of deaths per 100 patient-years of waiting in the DSA. Waiting time is
censored at transplant, death, transfer to another program, removal because
of improved condition, or end of cohort. Individual listings are counted sepa-




















Figure HR 35. Deaths within sixmonths after removal among adult heart
waitlist candidates, by status at removal. Denominator includes only can-
didates removed from the waiting list for reasons other than transplant or
death while on the list.














Figure HR 36. Deaths within sixmonths after removal among adult heart
waitlist candidates, by age at removal. Denominator includes only candi-
dates removed from thewaiting list for reasons other than transplant or death





















Figure HR 37. Deceased heart donor count by age. Count of deceased
donors whose hearts were recovered for transplant, by age at donation.













Figure HR 38. Distribution of deceased heart donors by age. Deceased


















Figure HR 39. Distribution of deceased heart donors by sex. Deceased
donors whose hearts were recovered for transplant.













Figure HR 40. Distribution of deceased heart donors by race. Deceased
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Figure HR 41. Percent of pediatric donor hearts allocated to adult recip-
ients, by DSA of donor hospital, 2014-2018. Numerator: pediatric donor
hearts donors allocated to adult recipients. Denominator: total pediatric
donor hearts.


















Figure HR 42. Rates of hearts recovered for transplant and not trans-
planted by donor age. Percentages of hearts not transplanted out of all























Figure HR 43. Rates of hearts recovered for transplant and not trans-
planted, by donor risk of disease transmission. ”Increased risk” is defined
by criteria from the US Public Health Service Guidelines for increased risk for
HIV, hepatitis B and hepatitis C transmission.














Figure HR 44. Cause of death among deceased heart donors. Deceased
























Figure HR 45. Total heart transplants. All heart transplant recipients, in-
cluding adult and pediatric, retransplant, and multi-organ recipients.




















FigureHR 46. Total heart transplants by age. All heart transplant recipients,






















FigureHR 47. Total heart transplants by sex. All heart transplant recipients,
including adult and pediatric, retransplant, and multi-organ recipients.




















Figure HR 48. Total heart transplants by race. All heart transplant recipi-

























Figure HR 49. Total heart transplants by diagnosis. All heart transplant
recipients, including adult and pediatric, retransplant, and multi-organ recipi-
ents. CAD, coronary artery disease.


















Figure HR 50. Total heart transplants by medical urgency. All heart trans-
plant recipients, including adult and pediatric, retransplant, and multi-organ
recipients. Urgency groups for recipients who underwent transplant October


















Figure HR 51. Induction agent use in adult heart transplant recipients.
Immunosuppression at transplant reported to the OPTN. IL2-RA, interleukin-2
receptor antagonist.

















Figure HR 52. Immunosuppression regimen use in adult heart transplant
recipients. Immunosuppression regimen at transplant reported to the OPTN.















Figure HR 53. Total HLA A, B, and DR mismatches among adult deceased
donor heart transplant recipients, 2014-2018. Donor and recipient antigen
matching is based on OPTN antigen values and split equivalences policy as of
2018.






















Figure HR 54. Annual adult heart transplant center volumes, by per-

























Figure HR 55. Distribution of adult heart transplants by annual center
volume. Based on annual volume data among recipients aged 18 or older.
















Figure HR 56. Patient survival among adult heart transplant recipients,
2011-2013, by age. Patient survival estimated using unadjusted Kaplan-Meier
methods. For recipients of more than one transplant during the period, only






















Figure HR 57. Patient survival among adult heart transplant recipients,
2011-2013, by race. Patient survival estimated using unadjusted Kaplan-
Meier methods. For recipients of more than one transplant during the period,
only the first is considered.
















Figure HR 58. Patient survival among adult heart transplant recipients,
2011-2013, by sex. Patient survival estimated using unadjusted Kaplan-Meier
methods. For recipients of more than one transplant during the period, only



















Figure HR 59. Patient survival among adult heart transplant recipients,
2011-2013, by circulatory support. Patient survival estimated using unad-
justed Kaplan-Meier methods. For recipients of more than one transplant
during the period, only the first is considered. Ventricular assist device (VAD)
status at time of transplant. IABP, intra-aortic balloon pump.















Figure HR 60. Patient survival among adult heart transplant recipients,
2011-2013, by first vs. retransplant. Patient survival estimated using un-
adjusted Kaplan-Meier methods. For recipients of more than one transplant





















Figure HR 61. Patient survival among adult heart transplant recipients,
2011-2013, bymedical urgency. Patient survival estimated using unadjusted
Kaplan-Meier methods. For recipients of more than one transplant during the
period, only the first is considered.















Figure HR 62. Patient survival among adult heart transplant recipients,
2011-2013, by metropolitan vs. non-metropolitan recipient residence.
Patient survival estimated using unadjusted Kaplan-Meier methods. For re-




















Figure HR 63. Patient survival among adult heart transplant recipients,
2011-2013, by recipients’ distance from transplant center. Patient survival
estimated using unadjusted Kaplan-Meier methods. For recipients of more
than one transplant during the period, only the first is considered. Distance is
between the zipcode centroids of the TX center and the recipient’s permanent
residence, measured in nautical miles (NM).
















Figure HR 64. Patient death among adult heart transplant recipients. All
adult recipients of deceased donor hearts, including multi-organ transplants.


























Figure HR 65. Recipients alive with a functioning heart graft on June 30
of the year, by age at transplant. Recipients are assumed to be alive with
function unless a death or graft failure is recorded. A recipientmay experience
a graft failure and be removed from the cohort, undergo retransplant, and re-
enter the cohort.









Figure HR 66. Incidence of acute rejection by 1 year posttransplant
among adult heart transplant recipients by age, 2016-2017. Acute rejec-
tion is defined as a record of acute or hyperacute rejection, as reported on
the OPTN Transplant Recipient Registration or Transplant Recipient Follow-up
Form. Only the first rejection event is counted. Cumulative incidence is esti-














Figure HR 67. Incidence of acute rejection by 1 year posttransplant
among adult heart transplant recipients by induction agent 2016-2017.
Acute rejection is defined as a record of acute or hyperacute rejection, as re-
ported on the OPTN Transplant Recipient Registration or Transplant Recipient
Follow-up Form. Only the first rejection event is counted. Cumulative inci-
dence is estimated using the Kaplan-Meier competing risk method. If a recip-























Figure HR 68. Incidence of PTLD among adult heart transplant recipients
by recipient EBV status at transplant, 2012-2016. Cumulative incidence is
estimated using the Kaplan-Meier competing risk method. PTLD is identified
as a reported complication or cause of death on the OPTN Transplant Recip-
ient Follow-up Form or the Posttransplant Malignancy Form as polymorphic
PTLD, monomorphic PTLD, or Hodgkin’s disease. Only the earliest date of




























Figure HR 69. One-year cumulative incidence of death by cause among
adult heart recipients, 2016-2017. Primary cause of death is as reported
on the OPTN Transplant Recipient Registration and Follow-up Forms. Other
causes of death include hemorrhage, trauma, nonadherence, unspecified
other, unknown, etc. Cumulative incidence is estimated using Kaplan-Meier
competing risk methods.
















Figure HR 70. Five-year cumulative incidence of death by cause among
adult heart recipients, 2012-2013. Primary cause of death is as reported
on the OPTN Transplant Recipient Registration and Follow-up Forms. Other
causes of death include hemorrhage, trauma, nonadherence, unspecified























Figure HR 71. New pediatric candidates added to the heart transplant
waiting list. A new candidate is one who first joined the list during the given
year, without having been listed in a previous year. Previously listed candi-
dates who underwent transplant and subsequently relisted are considered
new. Candidates concurrently listed at multiple centers are counted once. Ac-
tive and inactive patients are included. Age determined at listing.



















Figure HR 72. Pediatric candidates listed for heart transplant on De-
cember 31 each year. Candidates concurrently listed at multiple centers are




















FigureHR73. Distribution of pediatric candidateswaiting for heart trans-
plant by age. Candidates waiting for transplant at any time in the given year.
Candidates listed concurrently at multiple centers are counted once. Age is
determined at the later of listing date or January 1 of the given year. Active
and inactive candidates are included.














FigureHR74. Distribution of pediatric candidateswaiting for heart trans-
plant by race. Candidates waiting for transplant any time in the given year.
Candidates listed concurrently at multiple centers are counted once. Active



















FigureHR75. Distribution of pediatric candidateswaiting for heart trans-
plant by diagnosis. Candidates waiting for transplant any time in the given
year. Candidates listed concurrently at multiple centers are counted once. Ac-
tive and inactive candidates are included. CM, cardiomyopathy.












FigureHR76. Distribution of pediatric candidateswaiting for heart trans-
plant by sex. Candidates waiting for transplant any time in the given year.
Candidates listed concurrently at multiple centers are counted once. Active



















FigureHR77. Distribution of pediatric candidateswaiting for heart trans-
plant bywaiting time. Candidateswaiting for transplant any time in the given
year. Candidates listed concurrently at multiple centers are counted once.
Time on thewaiting list is determined at the earlier of December 31 or removal
from the waiting list. Active and inactive candidates are included.













FigureHR78. Distribution of pediatric candidateswaiting for heart trans-
plant by medical urgency. Candidates waiting for transplant any time in the
given year. Candidates listed concurrently at multiple centers are counted
once. Medical urgency status is the most severe during the year. Active and





















Figure HR 79. Three-year outcomes for newly listed pediatric candidates
waiting for heart transplant, 2015. Pediatric candidates who joined the
waitlist in 2015. Candidates concurrently listed at more than one center are
counted once, from the time of earliest listing to the time of latest removal.
DD, deceased donor.






























Figure HR 80. Deceased donor heart transplant rates among pediatric
waitlist candidates by age. Transplant rates are computed as the number of
deceased donor transplants per 100 patient-years of waiting in a given year.
Individual listings are counted separately. Age is determined at the later of
listing date or January 1 of the given year. Rates with less than 10 patient-


































Figure HR 81. Deceased donor heart transplant rates among pediatric
waitlist candidates by metropolitan vs. non-metropolitan residence.
Transplant rates are computed as the number of deceased donor transplants
per 100 patient-years of waiting in a given year. Individual listings are counted
separately. Rates with less than 10 patient-years of exposure or fewer than 20
candidates at risk are not shown.































Figure HR 82. Deceased donor heart transplant rates among pediatric
waitlist candidates by distance from listing center. Transplant rates are
computed as the number of deceased donor transplants per 100 patient-years
of waiting in a given year. Individual listings are counted separately. Rateswith
less than 10 patient-years of exposure or fewer than 20 candidates at risk are
not shown. Distance is between the zipcode centroids of the TX center and
































Figure HR 83. Pretransplant mortality rates among pediatrics waitlisted
for heart transplant by age. Mortality rates are computed as the number
of deaths per 100 patient-years of waiting in the given year. Waiting time
is censored at transplant, death, transfer to another program, removal be-
cause of improved condition, or end of cohort. Individual listings are counted
separately. Age is determined at the later of listing date or January 1 of the
given year. Individual listings are counted separately. Rates with less than 10




























Figure HR 84. Pretransplant mortality rates among pediatrics waitlisted
for heart transplant by race. Mortality rates are computed as the number
of deaths per 100 patient-years of waiting in the given year. Waiting time is
censored at transplant, death, transfer to another program, removal because
of improved condition, or end of cohort. Individual listings are counted sep-
arately. Rates with less than 10 patient-years of exposure or fewer than 20
































Figure HR 85. Pretransplant mortality rates among pediatrics waitlisted
for heart transplant by diagnosis. Mortality rates are computed as the num-
ber of deaths per 100 patient-years of waiting in the given year. Waiting time is
censored at transplant, death, transfer to another program, removal because
of improved condition, or end of cohort. Individual listings are counted sepa-






























Figure HR 86. Pretransplant mortality rates among pediatrics waitlisted
for heart transplant by medical urgency. Mortality rates are computed
as the number of deaths per 100 patient-years of waiting in the given year.
Waiting time is censored at transplant, death, transfer to another program,
removal because of improved condition, or end of cohort. Individual listings
are counted separately. Rates with less than 10 patient-years of exposure or
fewer than 20 candidates at risk are not shown. Medical urgency status is de-
































Figure HR 87. Pretransplant mortality rates among pediatrics waitlisted
for heart transplant by metropolitan vs. non-metropolitan residence.
Mortality rates are computed as the number of deaths per 100 patient-years
of waiting in the given year. Waiting time is censored at transplant, death,
transfer to another program, removal because of improved condition, or end
of cohort. Individual listings are counted separately. Rates with less than 10
patient-years of exposure are not shown. Urban/rural determination is made
































Figure HR 88. Pretransplant mortality rates among pediatrics waitlisted
for heart transplant by distance from listing center. Mortality rates are
computed as the number of deaths per 100 patient-years of waiting in the
given year. Waiting time is censored at transplant, death, transfer to another
program, removal because of improved condition, or end of cohort. Individ-
ual listings are counted separately. Rates with less than 10 patient-years of
exposure or fewer than 20 candidates at risk are not shown. Distance is be-
tween the zipcode centroids of the TX center and the recipient’s permanent

























Figure HR 89. Pediatric heart transplants by recipient age. All pediatric
heart transplant recipients, including retransplant and multi-organ recipients.















Figure HR 90. Number of centers performing pediatric and adult heart
transplants by center’s age mix. Adult centers transplanted only recipients
aged 18 years or older. Functionally adult centers transplant 80% adults or
more, and the remainder were children aged 15-17 years. Mixed included
adults and children of any age groups. Child only centers transplanted recipi-




















Figure HR 91. Pediatric heart recipients at programs that perform 5 or
fewer pediatric transplants annually. Age groups are cumulative.














Figure HR 92. Induction agent use in pediatric heart transplant re-




















Figure HR 93. Immunosuppression regimen use in pediatric heart trans-
plant recipients. Immunosuppression regimen at transplant reported to the
OPTN. Tac, tacrolimus. MMF, mycophenolate mofetil.














Figure HR 94. Induction use by C/PRA among pediatric heart transplant
recipients, 2014-2018. Collection of calculated PRA (CPRA) began March 31,
















Figure HR 95. Total HLA A, B, and DR mismatches among pediatric de-
ceased donor heart transplant recipients, 2014-2018. Donor and recipient
antigen matching is based on OPTN antigen values and split equivalences pol-
icy as of 2018.











Figure HR 96. Incidence of acute rejection by 1 year posttransplant
among pediatric heart transplant recipients by age, 2016-2017. Acute re-
jection is defined as a record of acute or hyperacute rejection, as reported
on the OPTN Transplant Recipient Registration Form or Transplant Recipient
Follow-up Form. Only the first rejection event is counted. Cumulative inci-
















Figure HR 97. Incidence of acute rejection by 1 year posttransplant
among pediatric heart transplant recipients by induction agent 2016-
2017. Acute rejection is defined as a record of acute or hyperacute rejection,
as reported on the OPTN Transplant Recipient Registration or Transplant Re-
cipient Follow-up Form. Only the first rejection event is counted. Cumulative
incidence is estimated using the Kaplan-Meier competing risk method. If a re-






















Figure HR 98. Incidence of PTLD among pediatric heart transplant recip-
ients by recipient EBV status at transplant, 2006-2016. Cumulative inci-
dence is estimated using the Kaplan-Meier competing risk method. Posttrans-
plant lymphoproliferative disorder (PTLD) is identified as a reported complica-
tion or cause of death on the OPTN Transplant Recipient Follow-up Form or
on the Posttransplant Malignancy Form as polymorphic PTLD, monomorphic
PTLD, or Hodgkin’s disease. Only the earliest date of PTLD diagnosis is consid-






















Figure HR 100. Patient survival among pediatric deceased donor heart
























Figure HR 101. One-year cumulative incidence of death by cause among
pediatric heart recipients, 2016-2017. Primary cause of death is as re-
ported on the OPTN Transplant Recipient Registration and Follow-up Forms.
Other causes of death include hemorrhage, trauma, nonadherence, unspec-
ified other, unknown, etc. Cumulative incidence is estimated using Kaplan-
Meier competing risk methods.















Figure HR 102. Five-year cumulative incidence of death by cause among
pediatric heart recipients, 2012-2013. Primary cause of death is as re-
ported on the OPTN Transplant Recipient Registration and Follow-up Forms.
Other causes of death include hemorrhage, trauma, nonadherence, unspec-
ified other, unknown, etc. Cumulative incidence is estimated using Kaplan-







N Percent N Percent
Age
18-34 years 267 10.8% 376 11.0%
35-49 years 564 22.9% 784 23.0%
50-64 years 1241 50.3% 1671 49.1%
≥ 65 years 394 16.0% 573 16.8%
Sex
Female 599 24.3% 825 24.2%
Male 1867 75.7% 2579 75.8%
Race/ethnicity
White 1807 73.3% 2080 61.1%
Black 447 18.1% 903 26.5%
Hispanic 163 6.6% 304 8.9%
Asian 37 1.5% 93 2.7%
Other/unknown 12 0.5% 24 0.7%
Geography
Metropolitan 1998 81.0% 2910 85.5%
Non-metro 468 19.0% 494 14.5%
Distance
< 50 miles 1388 56.3% 2114 62.1%
50-<100 miles 437 17.7% 543 16.0%
100-<150 miles 248 10.1% 325 9.5%
150-<250 miles 185 7.5% 219 6.4%
≥ 250 miles 181 7.3% 184 5.4%
Unknown 27 1.1% 19 0.6%
All candidates 2466 100.0% 3404 100.0%
Table HR 1Demographic characteristics of adults on the heart transplant
waiting list on December 31, 2008 and December 31, 2018. Candidates
waiting for transplant on December 31 of the given year, regardless of first
listing date; multiple listings are collapsed. Distance is computed from candi-







N Percent N Percent
Diagnosis
Coronary artery disease 1033 41.9% 1034 30.4%
Cardiomyopathy 1083 43.9% 1999 58.7%
Congenital disease 146 5.9% 174 5.1%
Valvular disease 50 2.0% 34 1.0%
Other/unknown 154 6.2% 163 4.8%
Blood type
A 779 31.6% 1015 29.8%
B 230 9.3% 369 10.8%
AB 31 1.3% 66 1.9%
O 1426 57.8% 1954 57.4%
VAD at listing 243 9.9% 1166 34.3%
All candidates 2466 100.0% 3404 100.0%
Table HR 2 Clinical characteristics of adults on the heart transplant wait-
ing list on December 31, 2008 and December 31, 2018. Candidates waiting
for transplant onDecember 31 of the given year, regardless of first listing date;







N Percent N Percent
Transplant history
First 2359 95.7% 3305 97.1%
Retransplant 107 4.3% 99 2.9%
Wait time
< 1 year 1240 50.3% 1772 52.1%
1-< 2 years 417 16.9% 725 21.3%
2-< 3 years 216 8.8% 365 10.7%
3-< 4 years 110 4.5% 210 6.2%
4-< 5 years 89 3.6% 145 4.3%
≥ 5 years 394 16.0% 187 5.5%
Tx type
Heart only 2286 92.7% 3118 91.6%
Heart-kidney 84 3.4% 206 6.1%
Heart-lung 78 3.2% 42 1.2%
Other 18 0.7% 38 1.1%
All candidates 2466 100.0% 3404 100.0%
Table HR 3 Listing characteristics of adults on the heart transplant wait-
ing list on December 31, 2008 and December 31, 2018. Candidates waiting
for transplant onDecember 31 of the given year, regardless of first listing date;







N Percent N Percent
Former status 1A 379 10.7% 0 0.0%
Former status 1B 1555 44.0% 0 0.0%
Former status 2 795 22.5% 0 0.0%
New status 1 0 0.0% 7 0.2%
New status 2 0 0.0% 64 1.9%
New status 3 0 0.0% 207 6.1%
New status 4 0 0.0% 1627 47.8%
New status 5 0 0.0% 86 2.5%
New status 6 0 0.0% 605 17.8%
Inactive 802 22.7% 808 23.7%
All 3531 100.0% 3404 100.0%
Table HR 4 Status of adults on the heartwaiting list onDecember 31, 2017
and December 31, 2018. Candidates waiting for transplant on December 31,
2017, and December 31, 2018, regardless of first listing date. Allocation by





Waiting list state 2016 2017 2018
Patients at start of year 3790 3629 3522
Patients added during year 3629 3769 3883
Patients removed during year 3783 3867 4001
Patients at end of year 3636 3531 3404
Table HR 5 Heart transplant waitlist activity among adults. Candidates
concurrently listed at more than one center are counted once, from the time
of earliest listing to the time of latest removal. Candidates who are listed, un-
dergo transplant, and are relisted are counted more than once. Candidates
are not considered to be on the list on the day they are removed; counts on
January 1 may differ from counts on December 31 of the prior year. Candi-





Removal reason 2016 2017 2018
Deceased donor transplant 2734 2811 2940
Patient died 324 290 268
Patient refused transplant 25 27 26
Improved, transplant not needed 187 176 180
Too sick for transplant 261 290 272
Other 251 271 315
TableHR 6Removal reason among adult heart transplant candidates. Re-
moval reason as reported to the OPTN. Candidates with death dates that pre-







N Percent N Percent
Any life support 1791 83.6% 2402 81.0%
Left ventricular assist device 953 44.5% 1295 43.6%
Intravenous inotropes 797 37.2% 979 33.0%
Intra-aortic balloon pump 123 5.7% 270 9.1%
Right ventricular assist device 73 3.4% 46 1.6%
Total artificial heart 55 2.6% 31 1.0%
Prostaglandins 27 1.3% 4 0.1%
Ventilator 17 0.8% 30 1.0%
Extra corporeal membrane oxygenation 15 0.7% 58 2.0%
Inhaled NO 3 0.1% 5 0.2%
Table HR 7 Adult heart recipients on circulatory support before trans-







N Percent N Percent
Age
18-34 years 213 11.7% 311 10.5%
35-49 years 427 23.5% 589 19.9%
50-64 years 925 50.9% 1407 47.4%
≥ 65 years 253 13.9% 660 22.2%
Sex
Female 454 25.0% 839 28.3%
Male 1364 75.0% 2128 71.7%
Race/ethnicity
White 1248 68.6% 1906 64.2%
Black 352 19.4% 654 22.0%
Hispanic 149 8.2% 261 8.8%
Asian 55 3.0% 122 4.1%
Other/unknown 14 0.8% 24 0.8%
Insurance
Private 978 53.8% 1348 45.4%
Medicare 548 30.1% 1120 37.7%
Medicaid 229 12.6% 365 12.3%
Other government 45 2.5% 97 3.3%
Unknown 18 1.0% 37 1.2%
Geography
Metropolitan 1496 82.3% 2498 84.2%
Non-metro 322 17.7% 469 15.8%
Distance
< 50 miles 1105 60.8% 1816 61.2%
50-<100 miles 290 16.0% 470 15.8%
100-<150 miles 176 9.7% 273 9.2%
150-<250 miles 131 7.2% 199 6.7%
≥ 250 miles 105 5.8% 151 5.1%
Unknown 11 0.6% 58 2.0%
All recipients 1818 100.0% 2967 100.0%
Table HR 8 Demographic characteristics of adult heart transplant recip-
ients, 2008 and 2018. Heart transplant recipients, including retransplants.







N Percent N Percent
Diagnosis
Coronary artery disease 735 40.4% 932 31.4%
Cardiomyopathy 962 52.9% 1823 61.4%
Congenital disease 51 2.8% 117 3.9%
Valvular disease 41 2.3% 29 1.0%
Other/unknown 29 1.6% 66 2.2%
Blood type
A 754 41.5% 1144 38.6%
B 267 14.7% 485 16.3%
AB 100 5.5% 144 4.9%
O 697 38.3% 1194 40.2%
On VAD 519 28.5% 1370 46.2%
CPRA
< 1% 1146 63.0% 1339 45.1%
1-< 20% 314 17.3% 334 11.3%
20-< 80% 223 12.3% 480 16.2%
80-< 98% 48 2.6% 107 3.6%
98-100% 17 0.9% 47 1.6%
Unknown 70 3.9% 660 22.2%
All recipients 1818 100.0% 2967 100.0%
Table HR 9 Clinical characteristics of adult heart transplant recipients,
2008 and 2018. Heart transplant recipients, including retransplants. Ventric-
ular assist device (VAD) information is from the OPTN Transplant Recipient
Registration Form and includes left VAD, right VAD, total artificial heart, and
left + right VAD. Collection of calculated PRA (CPRA) began March 31, 2015.







N Percent N Percent
Wait time
< 31 days 615 33.8% 858 28.9%
31-60 days 297 16.3% 431 14.5%
61-90 days 171 9.4% 278 9.4%
3-< 6 months 331 18.2% 443 14.9%
6-< 12 months 231 12.7% 413 13.9%
1-< 2 years 115 6.3% 312 10.5%
≥ 2 years 58 3.2% 232 7.8%
Transplant history
First 1755 96.5% 2873 96.8%
Retransplant 63 3.5% 94 3.2%
Tx type
Heart only 1723 94.8% 2697 90.9%
Heart-lung 20 1.1% 25 0.8%
Heart-kidney 63 3.5% 202 6.8%
Heart-liver 9 0.5% 38 1.3%
Other 3 0.2% 5 0.2%
All recipients 1818 100.0% 2967 100.0%
Table HR 10 Transplant characteristics of adult heart transplant recipi-







N Percent N Percent
Former status 1A 313 66.3% 1 0.2%
Former status 1B 146 30.9% 0 0.0%
Former status 2 13 2.8% 0 0.0%
New status 1 0 0.0% 36 7.9%
New status 2 0 0.0% 176 38.6%
New status 3 0 0.0% 130 28.5%
New status 4 0 0.0% 91 20.0%
New status 5 0 0.0% 1 0.2%
New status 6 0 0.0% 21 4.6%
All 472 100.0% 456 100.0%
Table HR 11 Status of adult heart transplant recipients, November-






Donor Recipient CMV EBV HIV
D- R- 17.5% 0.9% 97.1%
D- R+ 20.2% 6.8% 0.4%
D- R unk 0.9% 0.5% 2.2%
D+ R- 24.9% 8.8% 0.0%
D+ R+ 35.0% 77.2% 0.0%
D+ R unk 0.9% 5.5% 0.0%
D unk R- 0.3% 0.0% 0.3%
D unk R+ 0.3% 0.2% 0.0%
D unk R unk 0.0% 0.0% 0.0%
Table HR 12 Adult heart donor-recipient serology matching, 2016-2018.
Donor serology is reported on the OPTN Donor Registration Form and recipi-
ent serology on the OPTN Transplant Recipient Registration Form. There may
be multiple fields per serology. Any evidence for a positive serology is treated
as positive for that serology. CMV, cytomegalovirus; EBV, Epstein-Barr virus;







N Percent N Percent
Age
< 1 year 47 18.7% 49 14.0%
1-5 years 79 31.3% 131 37.5%
6-10 years 56 22.2% 73 20.9%
11-17 years 70 27.8% 96 27.5%
Sex
Female 115 45.6% 145 41.5%
Male 137 54.4% 204 58.5%
Race/ethnicity
White 142 56.3% 191 54.7%
Black 53 21.0% 63 18.1%
Hispanic 51 20.2% 69 19.8%
Asian 4 1.6% 8 2.3%
Other/unknown 2 0.8% 18 5.2%
Geography
Metropolitan 217 86.1% 285 81.7%
Non-metro 35 13.9% 64 18.3%
Distance
< 50 miles 126 50.0% 190 54.4%
50-<100 miles 50 19.8% 54 15.5%
100-<150 miles 26 10.3% 43 12.3%
150-<250 miles 23 9.1% 38 10.9%
≥ 250 miles 23 9.1% 19 5.4%
Unknown 4 1.6% 5 1.4%
All candidates 252 100.0% 349 100.0%
Table HR 13 Demographic characteristics of pediatric candidates on the
heart transplant waiting list on December 31, 2008 and December 31,
2018. Candidates aged younger than 18 years waiting for transplant on De-
cember 31 of given year, regardless of first listing date; multiple listings are col-
lapsed. Age calculated at snapshot. Candidates listed as children who turned
18 before the cohort date are excluded. Distance is computed from candi-







N Percent N Percent
Diagnosis
Congenital defect 121 48.0% 217 62.2%
Idiopathic dilated CM 60 23.8% 44 12.6%
Familial dilated CM 2 0.8% 9 2.6%
Idiopathic restrictive CM 10 4.0% 9 2.6%
Myocarditis 14 5.6% 8 2.3%
Other/unknown 45 17.9% 62 17.8%
Blood type
A 74 29.4% 108 30.9%
B 35 13.9% 45 12.9%
AB 4 1.6% 9 2.6%
O 139 55.2% 187 53.6%
Medical urgency
Status 1A 57 22.6% 96 27.5%
Status 1B 20 7.9% 70 20.1%
Status 2 49 19.4% 100 28.7%
Inactive status 126 50.0% 83 23.8%
VAD at listing 10 4.0% 23 6.6%
All candidates 252 100.0% 349 100.0%
Table HR 14 Clinical characteristics of pediatric candidates on the heart
transplantwaiting list onDecember 31, 2008andDecember 31, 2018. Can-
didates aged younger than 18 years waiting for transplant on December 31,
2008, and December 31, 2018, regardless of first listing date; multiple listings
are collapsed. Candidates listed as children who turned 18 before the cohort







N Percent N Percent
Transplant history
First 234 92.9% 327 93.7%
Retransplant 18 7.1% 22 6.3%
Wait time
< 1 year 140 55.6% 237 67.9%
1-< 2 years 33 13.1% 51 14.6%
2-< 3 years 19 7.5% 29 8.3%
3-< 4 years 15 6.0% 12 3.4%
4-< 5 years 11 4.4% 9 2.6%
≥ 5 years 34 13.5% 11 3.2%
Tx type
Heart only 236 93.7% 341 97.7%
Heart-kidney 1 0.4% 5 1.4%
Heart-lung 14 5.6% 2 0.6%
Other 1 0.4% 1 0.3%
All candidates 252 100.0% 349 100.0%
Table HR 15 Listing characteristics of pediatric candidates on the heart
transplantwaiting list onDecember 31, 2008andDecember 31, 2018. Can-
didates aged younger than 18 years waiting for transplant on December 31,
2008, and December 31, 2018, regardless of first listing date; multiple listings






Waiting list state 2016 2017 2018
Patients at start of year 369 367 384
Patients added during year 626 623 685
Patients removed during year 627 606 674
Patients at end of year 368 384 395
Table HR 16 Heart transplant waitlist activity among pediatric candi-
dates. Candidates concurrently listed at more than one center are counted
once, from the time of earliest listing to the time of latest removal. Candi-
dates who are listed, undergo transplant, and are relisted are counted more
than once. Candidates are not considered to be on the list on the day they are
removed; counts on January 1 may differ from counts on December 31 of the





Removal reason 2016 2017 2018
Deceased donor transplant 460 444 486
Patient died 61 67 77
Patient refused transplant 2 0 2
Improved, transplant not needed 60 54 62
Too sick for transplant 28 28 31
Other 16 13 16
Table HR 17 Removal reason among pediatric heart transplant candi-
dates. Removal reason as reported to the OPTN. Candidates with death dates







N Percent N Percent
Age
< 1 year 280 27.4% 361 26.7%
1-5 years 254 24.8% 322 23.9%
6-10 years 141 13.8% 170 12.6%
11-17 years 348 34.0% 497 36.8%
Sex
Female 457 44.7% 591 43.8%
Male 566 55.3% 759 56.2%
Race/ethnicity
White 556 54.3% 694 51.4%
Black 219 21.4% 269 19.9%
Hispanic 176 17.2% 285 21.1%
Asian 51 5.0% 61 4.5%
Other/unknown 21 2.1% 41 3.0%
Insurance
Private 529 51.7% 533 39.5%
Medicaid 391 38.2% 688 51.0%
Other government 70 6.8% 95 7.0%
Unknown 33 3.2% 34 2.5%
Geography
Metropolitan 849 83.0% 1108 82.1%
Non-metro 174 17.0% 242 17.9%
Distance
< 50 miles 525 51.3% 725 53.7%
50-<100 miles 148 14.5% 246 18.2%
100-<150 miles 110 10.8% 129 9.6%
150-<250 miles 98 9.6% 114 8.4%
≥ 250 miles 119 11.6% 104 7.7%
Unknown 23 2.2% 32 2.4%
All recipients 1023 100.0% 1350 100.0%
Table HR 18 Demographic characteristics of pediatric heart transplant
recipients, 2006-2008 and 2016-2018. Pediatric heart transplant recipients,
including retransplants. Distance is computed from recipient’s home zip code







N Percent N Percent
Diagnosis
Congenital defect 430 42.0% 677 50.1%
Idiopathic dilated CM 300 29.3% 291 21.6%
Familial dilated CM 37 3.6% 77 5.7%
Idiopathic restrictive CM 65 6.4% 63 4.7%
Myocarditis 44 4.3% 31 2.3%
Other/unknown 147 14.4% 211 15.6%
Blood type
A 372 36.4% 472 35.0%
B 131 12.8% 193 14.3%
AB 37 3.6% 46 3.4%
O 483 47.2% 639 47.3%
Medical urgency
Status 1A 788 77.0% 1082 80.1%
Status 1B 130 12.7% 227 16.8%
Status 2 105 10.3% 41 3.0%
On VAD 134 13.1% 384 28.4%
CPRA
< 1% 597 58.4% 519 38.4%
1-< 20% 159 15.5% 190 14.1%
20-< 80% 118 11.5% 266 19.7%
80-< 98% 36 3.5% 71 5.3%
98-100% 28 2.7% 51 3.8%
Unknown 85 8.3% 253 18.7%
All recipients 1023 100.0% 1350 100.0%
Table HR 19 Clinical characteristics of pediatric heart transplant recip-
ients, 2006-2008 and 2016-2018. Heart transplant recipients, including re-
transplants. Collection of calculated PRA (CPRA) began March 31, 2015. Prior








N Percent N Percent
Wait time
< 31 days 468 45.7% 374 27.7%
31-60 days 190 18.6% 234 17.3%
61-90 days 116 11.3% 207 15.3%
3-< 6 months 129 12.6% 274 20.3%
6-< 12 months 76 7.4% 147 10.9%
1-< 2 years 26 2.5% 78 5.8%
≥ 2 years 18 1.8% 36 2.7%
ABO
Compatible/identical 989 96.7% 1216 90.1%
Incompatible 34 3.3% 134 9.9%
Transplant history
First 958 93.6% 1300 96.3%
Retransplant 65 6.4% 50 3.7%
Tx type
Heart only 997 97.5% 1334 98.8%
Heart-lung 16 1.6% 7 0.5%
Heart-kidney 7 0.7% 7 0.5%
Heart-liver 3 0.3% 2 0.1%
All recipients 1023 100.0% 1350 100.0%
Table HR 20 Transplant characteristics of pediatric heart transplant re-








N Percent N Percent
Any life support 318 77.4% 349 73.8%
Intravenous inotropes 221 53.8% 226 47.8%
Left ventricular assist device 107 26.0% 141 29.8%
Ventilator 62 15.1% 59 12.5%
Right ventricular assist device 23 5.6% 27 5.7%
Extra corporeal membrane oxygenation 20 4.9% 16 3.4%
Prostaglandins 7 1.7% 10 2.1%
Inhaled NO 4 1.0% 8 1.7%
Intra-aortic balloon pump 3 0.7% 0 0.0%
Total artificial heart 0 0.0% 3 0.6%
Table HR 21 Pediatric heart recipients on circulatory support before





Donor Recipient CMV EBV
D- R- 33.8% 17.1%
D- R+ 14.9% 14.7%
D- R unk 1.1% 1.4%
D+ R- 28.1% 28.7%
D+ R+ 20.4% 36.2%
D+ R unk 0.7% 1.6%
D unk R- 0.7% 0.0%
D unk R+ 0.3% 0.3%
D unk R unk 0.0% 0.0%
Table HR 22 Pediatric heart donor-recipient serology matching, 2016-
2018. Donor serology is reported on the OPTN Donor Registration Form and
recipient serology on the OPTN Transplant Recipient Registration Form. There
may be multiple fields per serology. Any evidence for a positive serology is
treated as positive for that serology. CMV, cytomegalovirus; EBV, Epstein-Barr
virus.
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